We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis’ blockbuster multiple sclerosis drug Gilenya (fingolimod) may soon face generic competitors in the U.S., following three FDA approvals. Read More
House Speaker Nancy Pelosi announced yesterday that drug pricing measure H.R. 3 is headed to a House floor vote next week, where it is expected to pass. But because there is no Senate companion measure, there is unlikely to be final legislation on drug pricing this year. Read More
The FDA continued to lead the world in new molecular entity approvals in fiscal year 2019, according to a senior official in the Office of New Drugs. Read More
The White House Council of Economic Advisers yesterday joined in the debate over the impact of H.R. 3, a drug pricing bill currently awaiting a vote on the House floor. Read More